Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
10/09/17
Preliminary Data from TOUR™ Observational Patient Registry Demonstrate Clinical Response Rates with VIBATIV® (telavancin) Treatment Range from 64.9 - 72.6% for Patients with Bone and Joint Infections, Bacteremia and Infective Endocarditis Additional Study Results Demonstrate VIBATIV to be 8-Fold
10/03/17
Preliminary Data from TOUR™ Observational Patient Registry Highlights Positive Clinical Response Rates Against Bone and Joint Infections, Bacteremia and Infective Endocarditis Additional VIBATIV Study Results Demonstrate Greater in vitro Potency than Competitor Antibiotics Against
09/20/17
Single Inhaler Triple Therapy Met Study Primary Endpoint Demonstrating Reduction in Exacerbations Compared with Dual Therapies Anoro Ellipta and Relvar/Breo Ellipta in Patients with COPD Theravance Biopharma Entitled to Receive 85% Economic Interest in Trelegy Ellipta Royalties Paid by
09/19/17
DUBLIN , Sept. 19, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will present a corporate overview at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2017 at 9:10 a.m. ET .
09/19/17
Theravance Biopharma Entitled to Receive 85% Economic Interest in Trelegy Ellipta Royalties Paid by GlaxoSmithKline as Part of Agreement with Innoviva DUBLIN , Sept. 19, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") today highlighted that the US Food and
09/18/17
Theravance Biopharma Entitled to Receive 85% Economic Interest in Closed Triple Royalties Paid by GSK as Part of Agreement with Innoviva DUBLIN, Ireland , Sept. 18, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") today highlighted that GlaxoSmithKline plc
09/05/17
DUBLIN , Sept. 5, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in a fireside chat at the Morgan Stanley 15th Annual Global Healthcare Conference on Tuesday, September 12, 2017 at 8:00 a.m. ET .
08/08/17
Meaningful Clinical Readouts Underpin Progress in Key Programs Additional Milestones Anticipated in Remainder of 2017 and 2018 DUBLIN , Aug. 8, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today reported financial results for the second
08/08/17
Evidence of Localized Target Engagement after Four Weeks of Treatment Minimal Systemic Exposure No Evidence of Systemic Immunosuppression or Infections Company Plans to Progress TD-1473 into Induction and Maintenance Study in 2018 DUBLIN , Aug. 8, 2017 /PRNewswire/ --  Theravance Biopharma, Inc.
08/02/17
Improvements in Symptoms and Normalized Gastric Emptying Demonstrated in both Diabetic and Idiopathic Gastroparesis Patients DUBLIN, Ireland , Aug. 2, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced positive results from a